Survodutide: Strong Phase 2 data and a first Phase 3 readout, but still investigational

Survodutide (its lab code is BI 456906) is an experimental injectable drug being studied for obesity, fatty-liver disease, and type 2 diabetes. It has more real human research behind it than most peptides sold online, including several carefully run trials that compared it against a placebo (a dummy injection) and one positive early readout from a large final-stage study. Even so, as of June 2026 it is not approved for sale anywhere, and that final-stage data has not yet been checked and published by outside experts.

What it is

Survodutide is a peptide you take once a week as a shot under the skin. Chemically, it is a tweaked version of a natural hormone called glucagon, built from 29 amino acids (the small building blocks that make up proteins). It is designed to last a long time in the body: one of its amino acids has been swapped for an unusual one that the body’s enzymes can’t easily chew up, one end of the molecule is capped to protect it, and a long fatty chain lets it grab onto a blood protein called albumin so it can stay in circulation for days.

It works as a “dual agonist,” which just means it switches on two different receptors (the docking sites on cells that trigger a response): the GLP-1 receptor and the glucagon receptor. When tested on human cells in the lab, it hits both about equally hard (the technical strength measures, called EC₅₀, were roughly 0.33 nM for GLP-1 and 0.52 nM for glucagon — lower numbers mean more potent). But at the doses people would actually use, it fully turns on the GLP-1 receptor while only partly turning on the glucagon receptor, so in practice it leans more toward the GLP-1 side.

Here’s the thinking behind that design. The GLP-1 side reduces appetite and slows how fast the stomach empties, which helps people eat less. The glucagon side is believed to add a couple of extra benefits: burning more energy and acting directly on the liver. The glucagon part is kept deliberately low because, in theory, too much glucagon signaling could push blood sugar up. The drug is being developed by Boehringer Ingelheim and is still experimental.

The claims

Since survodutide isn’t sold as a real medicine, the only place ordinary people run into it is through “research chemical” sellers who label it “for research use only, not for human consumption.” The marketing usually pitches it as a cutting-edge fat-loss and liver drug you can buy right now, sometimes quoting the weight-loss numbers from the trials as if they automatically apply to whatever is inside the vial. Both of those claims — that it works that well, and that what you’re buying is the real thing — deserve a hard look.

The evidence

The human research is genuine and, compared to the usual gray-market peptide, surprisingly solid. There have been three separate trials that were randomized (people assigned to groups by chance), double-blind (neither the patients nor the doctors knew who got the real drug), and placebo-controlled. All three were Phase 2 studies (mid-stage testing) and all were paid for by the developer, Boehringer Ingelheim.

In a 46-week obesity study looking for the right dose (le Roux et al., Lancet Diabetes & Endocrinology, 2024), 386 treated adults with a BMI of 27 or higher and no diabetes took part. Average weight loss reached about 14.9% at the highest dose, versus 2.8% for placebo. But side effects were common: 91% of people on survodutide reported some kind of side effect (75% of them stomach-and-gut related), and 25% quit the study because of side effects, compared to just 4% on placebo.

In a 48-week study in MASH (Sanyal et al., New England Journal of Medicine, 2024) — that’s the fatty-liver disease — adults had the condition confirmed by biopsy (a tissue sample) along with fibrosis (liver scarring). The registry lists 295 enrolled, and 293 were analyzed in the published paper. The main goal was improving MASH on a follow-up biopsy without the scarring getting worse. That goal was reached in 47%, 62%, and 43% of people across the three doses, versus 14% on placebo. A drop in liver fat of at least 30% happened in roughly 57–63% of people on the drug, versus 14% on placebo.

In a 16-week type 2 diabetes study (Blüher, Rosenstock et al., Diabetologia, 2024), 411 treated adults already on metformin took part, and the study also included an open-label semaglutide group for comparison (semaglutide is the well-known drug behind Ozempic and Wegovy). Survodutide lowered HbA1c (a measure of average blood sugar over a few months) by up to about 1.71% and produced weight loss of up to about 8.7% (8.4 kg), versus 5.3% (5.2 kg) with semaglutide. Tolerability was again a hurdle: 77.8% of people on survodutide had a side effect versus about 52% on semaglutide or placebo, and 15.9% quit because of side effects.

In April 2026, the developer announced positive early results from the first Phase 3 trial (the large, final stage of testing), called SYNCHRONIZE-1, in obesity over 76 weeks: up to 16.6% weight loss versus 3.2% on placebo, with 85.1% of participants losing at least 5% of their body weight versus 38.8% on placebo. Both of the trial’s main goals were met.

So why does this stay graded “Preliminary” (grade 6) rather than “Strong” (grade 8–10)? A few reasons. The Phase 3 result so far is only a company press release — it hasn’t been reviewed by independent experts or formally published (the full data is expected at a June 2026 conference), and every other use is still only at Phase 2. All the published results come from the manufacturer, with company staff serving as authors and co-inventors, which is a real conflict-of-interest concern. The published studies were short (16 to 48 weeks), and there’s no long-term data on safety, on whether the benefits last, or on the outcomes that matter most (like heart attacks or worsening cirrhosis). No independent group outside the sponsor has reproduced the findings yet. And the Phase 3 MASH program (called LIVERAGE) hasn’t reported any results.

Safety and side effects

In the trials, the biggest issue by far was the stomach and gut — nausea, vomiting, diarrhea, and constipation. These got worse at higher doses and were the number-one reason people dropped out. As noted above, quitting because of side effects ran around 16% in the diabetes study and 25% in the obesity study at the doses that worked. One later re-analysis of the obesity trial reported improvements in blood pressure.

There are also concerns the trials didn’t fully capture. Turning on the glucagon receptor can speed up heart rate and, in theory, raise blood sugar. And the wider GLP-1 drug family carries warnings on its labels, including gallbladder problems, a possible link to pancreatitis (inflammation of the pancreas) that’s still being studied, and a thyroid-tumor signal seen in rodents whose meaning for humans is unclear. Long-term safety for survodutide itself simply isn’t established. On top of all that, none of the trial safety data applies to unregulated gray-market product, which carries extra, unmeasured risks — independent testing of peptides bought online routinely turns up products that are under-dosed, contaminated, or even the wrong molecule entirely. Nothing here is medical advice.

Legal and regulatory status

Survodutide is not approved by the FDA or any other regulator, for any use, as of June 2026. In October 2024 the FDA gave it Breakthrough Therapy designation for non-cirrhotic MASH with moderate-to-advanced fibrosis. That designation only speeds up the review process — it is not an approval and not proof that the drug works. Phase 3 programs are still running in obesity (the SYNCHRONIZE program, with SYNCHRONIZE-1 reporting positive early results in April 2026 plus an attached study on heart-related outcomes) and in MASH (LIVERAGE).

Because it isn’t sold as a real medicine, anything marketed as “survodutide” is unapproved and unregulated, skipping past FDA oversight and the manufacturing, purity, and sterility standards (known as GMP) that real drugs must meet. There is no quality check on any material a consumer might get hold of.

For athletes: survodutide is not specifically named on WADA’s 2026 Prohibited List, and the GLP-1 class as a whole is not banned — semaglutide and tirzepatide are on WADA’s 2026 Monitoring Program (meaning they are being watched for possible misuse), not prohibited, although a future ban is reportedly being considered. That said, because survodutide is an unapproved experimental drug, it could fall under WADA category S0, which bans any drug not approved by any health authority for human use. Any competing athlete should treat its status as unsettled and check directly with their anti-doping authority.

Bottom line

Survodutide has a genuine, well-designed base of human research — three placebo-controlled Phase 2 trials and one positive Phase 3 early readout — which puts it well ahead of the typical gray-market peptide. But it is still experimental: the Phase 3 data hasn’t been independently reviewed yet, every study so far was funded by the maker and ran only short-term, and the drug isn’t approved or legally available anywhere. Stomach-and-gut side effects keep showing up as a real limitation. And anything sold online today is unapproved and unverified.

Sources

• Sanyal AJ, et al. A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis. NEJM. 2024.
• ClinicalTrials.gov. Survodutide (BI 456906) MASH trial, NCT04771273.
• le Roux CW, et al. Survodutide for obesity: a phase 2 dose-finding trial. The Lancet Diabetes & Endocrinology. 2024.
• Blüher M, Rosenstock J, et al. Survodutide in type 2 diabetes: a phase 2 trial. Diabetologia. 2024.
• Zummo FP, et al. Discovery and pharmacology of survodutide (BI 456906). Molecular Metabolism. 2022.
• Thomas L, et al. Pharmacological profiling of survodutide. Diabetes, Obesity and Metabolism. 2024.
• SYNCHRONIZE-1 and SYNCHRONIZE-2 Phase 3 trial design. Obesity. 2025.
• Boehringer Ingelheim. Survodutide achieved 16.6% weight loss in Phase 3 SYNCHRONIZE-1 (topline). April 2026.
• Boehringer receives FDA Breakthrough Therapy designation and initiates two Phase 3 MASH trials for survodutide. October 2024.
• WADA Prohibited List portal. World Anti-Doping Agency.
• NADA summary of the WADA 2026 Prohibited List and Monitoring Program.
• Roux CW, et al. Blood-pressure effects of survodutide (post-hoc analysis). Diabetes, Obesity and Metabolism. 2025.
• The Hill. Health concerns over gray-market injectable peptides.
• Survodutide. Wikipedia.